Literature DB >> 30923817

Comparative Analysis of the Antiviral Effects Mediated by Type I and III Interferons in Hepatitis B Virus-Infected Hepatocytes.

Jan-Hendrik Bockmann1,2,3, Daniela Stadler1, Yuchen Xia1,4, Chunkyu Ko1, Jochen M Wettengel1, Julian Schulze Zur Wiesch2,3, Maura Dandri2,3, Ulrike Protzer1,3.   

Abstract

BACKGROUND: Type III interferons (IFNs) (λ1-3) activate similar signaling cascades as type I IFNs (α and β) via different receptors. Since IFN-α and lymphotoxin-β activate cytosine deamination and subsequent purging of nuclear hepatitis B virus (HBV) DNA, we investigated whether IFN-β and -λ may also induce these antiviral effects in differentiated HBV-infected hepatocytes.
METHODS: After determining the biological activity of IFN-α2, -β1, -λ1, and -λ2 in differentiated hepatocytes, their antiviral effects were analyzed in HBV-infected primary human hepatocytes and HepaRG cells.
RESULTS: Type I and III IFNs reduced nuclear open-circle DNA and covalently closed circular DNA (cccDNA) levels in HBV-infected cells. IFN-β and -λ were at least as efficient as IFN-α. Differential DNA-denaturing polymerase chain reaction and sequencing analysis revealed G-to-A sequence alterations of HBV cccDNA in IFN-α, -β, and -λ-treated liver cells indicating deamination. All IFNs induced apolipoprotein B messenger RNA-editing enzyme-catalytic polypeptide-like (APOBEC) deaminases 3A and 3G within 24 hours of treatment, but IFN-β and -λ induced longer-lasting expression of APOBEC deaminases in comparison to IFN-α.
CONCLUSIONS: IFN-β, IFN-λ1, and IFN-λ2 induce cccDNA deamination and degradation at least as efficiently as IFN-α, indicating that these antiviral cytokines are interesting candidates for the design of new therapeutic strategies aiming at cccDNA reduction and HBV cure.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  HBV; HepaRG cells; interferon-beta; interferon-lambda; primary human hepatocytes

Mesh:

Substances:

Year:  2019        PMID: 30923817     DOI: 10.1093/infdis/jiz143

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  10 in total

Review 1.  Hepatitis B virus cccDNA: Formation, regulation and therapeutic potential.

Authors:  Yuchen Xia; Haitao Guo
Journal:  Antiviral Res       Date:  2020-05-22       Impact factor: 5.970

Review 2.  Novel therapeutic strategies for chronic hepatitis B.

Authors:  Sandra Phillips; Ravi Jagatia; Shilpa Chokshi
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

Review 3.  Revisiting Hepatitis B Virus: Challenges of Curative Therapies.

Authors:  Jianming Hu; Ulrike Protzer; Aleem Siddiqui
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

4.  Toll-like receptor dual-acting agonists are potent inducers of PBMC-produced cytokines that inhibit hepatitis B virus production in primary human hepatocytes.

Authors:  Ivan Hirsch; Jan Weber; Vaclav Janovec; Jan Hodek; Kamila Clarova; Tomas Hofman; Pavel Dostalik; Jiri Fronek; Jaroslav Chlupac; Laurence Chaperot; Sarah Durand; Thomas F Baumert; Iva Pichova; Barbora Lubyova
Journal:  Sci Rep       Date:  2020-07-29       Impact factor: 4.379

Review 5.  Intracellular interferon signalling pathways as potential regulators of covalently closed circular DNA in the treatment of chronic hepatitis B.

Authors:  Zhi Yi Goh; Ee Chee Ren; Hui Ling Ko
Journal:  World J Gastroenterol       Date:  2021-04-14       Impact factor: 5.742

Review 6.  The Role of APOBECs in Viral Replication.

Authors:  Wendy Kaichun Xu; Hyewon Byun; Jaquelin P Dudley
Journal:  Microorganisms       Date:  2020-11-30

Review 7.  Interaction between the Hepatitis B Virus and Cellular FLIP Variants in Viral Replication and the Innate Immune System.

Authors:  Ah Ram Lee; Yong Kwang Park; Mehrangiz Dezhbord; Kyun-Hwan Kim
Journal:  Viruses       Date:  2022-02-11       Impact factor: 5.048

Review 8.  Recent Advances in Hepatitis B Treatment.

Authors:  Georgia-Myrto Prifti; Dimitrios Moianos; Erofili Giannakopoulou; Vasiliki Pardali; John E Tavis; Grigoris Zoidis
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-01

Review 9.  Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies.

Authors:  Laura A Novotny; John Grayson Evans; Lishan Su; Haitao Guo; Eric G Meissner
Journal:  Viruses       Date:  2021-06-09       Impact factor: 5.048

10.  Clearing of Foreign Episomal DNA from Human Cells by CRISPRa-Mediated Activation of Cytidine Deaminases.

Authors:  Sergey Brezgin; Anastasiya Kostyusheva; Natalia Ponomareva; Viktoriia Volia; Irina Goptar; Anastasiya Nikiforova; Igor Shilovskiy; Valery Smirnov; Dmitry Kostyushev; Vladimir Chulanov
Journal:  Int J Mol Sci       Date:  2020-09-18       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.